explore -WSS

explore

author：hotspot 2025-09-28 00:47:56 - browse：37

Home health and hospice chain Amedisys has chosen a new corporate owner.

Amedisys and UnitedHealth Group’s Optum agreed to a deal Monday in which UnitedHealth will pay $101 per share in cash for Amedisys, totaling $3.3 billion. UnitedHealth’s latest offer is $1 per share higher than what it proposed in its unsolicited buyout offer a few weeks ago.

Option Care Health, a company that delivers intravenous medicines and mails health care supplies to people’s homes, originally offered to acquire Amedisys in May in an all-stock deal. However, the attractiveness of that deal deteriorated after Option Care’s stock price plummeted soon after the company made its bid.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Medical records are filled with copy
Next article： Oak trusses raised to roof of fire

focus

WSS

Readout Newsletter: Parkinson's study, Gilead, CG Oncology

Biden launches a new push to limit health care costs

Elizabeth Holmes on track for early release from her 11

Petition to FDA: Get the lead out of consumer hair dyes

NIH fellows want a pay raise. Will that mean less money for grants?

Living with Fabry disease, a condition that causes chronic pain

hotspot

explore

hotspot

Activists slam private health insurers over coverage restrictions

Elizabeth Holmes on track for early release from her 11

Virginia high school admissions case could be legal follow

HCA discloses massive data breach affecting 11 million patients

Virginia high school admissions case could be legal follow

Leqembi, other new Alzheimer’s drugs require better biomarkers

How one medical school became remarkably diverse

Dog Aging Project founders on what lies ahead after losing funding

Hollywood unions extend contract negotiations for actors

NIH fellows want a pay raise. Will that mean less money for grants?

explore

There's an unseen cost to disruptive road

FDA sets aggressive timeline for overhauling inspection procedures

Leqembi, other new Alzheimer’s drugs require better biomarkers

FDA sets aggressive timeline for overhauling inspection procedures

New research casts further doubt on a common procedure used with IVF

It's time to get medical device identifiers over the finish line

hotspot

hotspot

focus

leisure time